Apologies for fragmented post.
The clinical results from the recent trials do provide evidence of the pre - post clinical findings (impressive and significant improvements achieved with the DURAVR). The clinical results also show superiority over the competitors products...specifically, the mechanical readings - area of valve and pressure gradient.
The cited article (sample of 80 in two groups - mechanical v bioprosthetic valves) highlited a difference between the two......particularly with the exercise tollerence results......the patients recieving the mechanical valve achieved significant improvements in the 6 minute walk test, yet the bioprosthetic valve shows no improvement.
Perhaps this is another area of superiority our product has - the bioprosthetic valve space.
- Forums
- ASX - By Stock
- AVR
- Ann: AGM Chairman Address and CEO Presentation
Ann: AGM Chairman Address and CEO Presentation, page-26
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.70 |
Change
-1.350(7.92%) |
Mkt cap ! $301.7M |
Open | High | Low | Value | Volume |
$16.50 | $16.50 | $15.52 | $571.1K | 35.69K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13 | $15.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.00 | 775 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13 | 15.580 |
2 | 320 | 15.560 |
1 | 2496 | 15.550 |
2 | 558 | 15.530 |
3 | 765 | 15.520 |
Price($) | Vol. | No. |
---|---|---|
16.000 | 775 | 2 |
16.200 | 500 | 1 |
16.500 | 63 | 1 |
17.100 | 900 | 1 |
17.500 | 511 | 2 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online